At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
In Brief
A Phase 3 clinical trial evaluating Granisetron, Ondansetron, and 2 other interventions for Cancer of the Cervix. Completed, enrolled 76 participants across 2 sites.
Detailed Summary
The goal of this clinical research study is to compare granisetron (when given through a patch) to ondansetron (when taken by mouth) for reducing nausea and vomiting in women with cervical, endometrial, or vaginal cancer having chemoradiation. Granisetron and ondansetron are designed to help reduce nausea and vomiting.
Study Details
Timeline
Interventions
34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
Completion of 3 questionnaires at study visits taking about 5 minutes each time.
Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.